An observational study in Lupus Nephritis, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Sun Yat-sen University · Observational
Among 95 studies in Lupus Nephritis with a site in China — 42 open to participants now, 45 under way, 8 of them phase 3. Lupus Nephritis · China.
Among the 95 studies in Lupus Nephritis with a site in China, this one is one of 2 that started in 2013, is one of 7 observational ones, reaches primary completion later than 41 of the 44 other live ones, and was the 30th registered.
340 studies on the registry are indexed under Lupus Nephritis; 135 are open to participants now.
Browse Lupus Nephritis studies →42 of the 95 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Beijing GoBroad Hospital · Sites in China
Beijing Biotech · Sites in China
Nanjing University School of Medicine · Sites in China
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 51 (58%) stop at 75 or younger; 29 take children under 18; 7 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 30 · Phase 3 22 · Phase 4 7
First in 1996; this study’s year is marked. 2 started in 2013.
This study's planned enrollment of 5,000 is above the median of 100 across 77 observational studies indexed under Lupus Nephritis.
Median enrollment 50 across the 87 interventional studies, 400 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 95 have an industry lead sponsor. The 10 most frequent:
Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 619 are open to participants now.
Sun Yat-sen University has 5 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
17 of the studies in Lupus Nephritis with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06406205Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | 2027-06 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT07706998Nanjing UniversityApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis | 2026-12-31 |
Among the 95 studies in Lupus Nephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are registering LN patients at recruited hospitals and developing a LN database in China. Patients will be follow-up every year, and both baseline and follow-up information will be entered into the registration system.
The investigators are registering Lupus nephritis (LN) and developing a LN database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education etc.), clinical characteristics (including systolic blood pressure, diastolic blood pressure, and lab measurements of whole blood, serum, urine etc.), complications, drug information at the baseline will be collected. Patients will be follow-up every year, the demographic and clinical characteristics, complications; drug information of patients will be collected at each visit. We will also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), end-stage renal disease (ESRD) or serum creatinine doubling. The patient survival and renal survival will be compared using the LN database.
Lupus nephritis patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosis as lupus nephritis
Other: No Intervention
Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
All-cause mortality and cardiovascular mortality of LN patients
Time frame: 10years
A composite renal outcome of LN patients
The composite renal outcome defined as doubling of serum creatinine and ESRD (defined as initiation of dialysis or kidney transplantation).
Time frame: 10years
Plan to share: Yes
Started Nov 2013 (actual). Primary completion is estimated for Dec 2029, 193 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.